Rivus posts a win for its experimental obesity drug in heart failure patients

Rivus Pharmaceuticals’ experimental cardiometabolic drug, HU6, nailed a mid-stage trial in obese patients with heart failure, finding that patients notched a statistically significant reduction in …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Publication of results for the 3rd quarter 2022/23 (ending 30 June 2023) on 24 August 2023 – Biotech Investments

EQS-News: Douglas GmbH / Key word(s): Interim Report/9 Month figures Douglas GmbH: Publication of results for the 3rd quarter 2022/23 (ending 30 June 2023) on

August 18, 2023

Regeneron wins EU approval for lymphoma bispecific following FDA rejection

EU regulatory authorities granted conditional approval to Regeneron’s bispecific antibody odronextamab for two forms of lymphoma. It’s Regeneron’s first bispecific antibody approval in the world

August 27, 2024

UNF professor secures NIH grant to investigate enzyme’s role in muscle atrophy

A University of North Florida biology professor has been awarded a prestigious four-year National Institutes of Health (NIH) grant totaling over $720K to study the

October 3, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.